Ascentage Pharma: Ascentage Pharma (http://6855.HK) is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage Pharma has built a pipeline of eight clinical drug candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has been conducting 28 Phase I/II clinical trials to evaluate the eight drug candidates in the United States, Australia, and China.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Oncology, Ophthalmology
9400 Key West Avenue, Suite 280
Rockville, MD 20850

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Ascentage Pharma Group International

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 1.30 2,693,500 0.00 Funds 2020-06-30
China Southern Asset Management Co., Ltd. 0.00 11,000 0.00 Funds 2019-12-31
Schroder Investment Management (Hong Kong) Ltd. 0.00 5,430 0.00 Funds 2019-12-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.